Sunday, 27 July 2014 09:28

Anticoagulation news items. Week commencing 21st July 2014

Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial

The Lancet
Antepartum prophylactic dalteparin did not reduce occurrence of VTE, pregnancy loss, or placenta-mediated pregnancy complications in pregnant women with thrombophilia at high risk of these complications and was associated with an increased risk of minor bleeding (n=289).

 

BMJ investigation alleges that Boehringer Ingelheim withheld safety analyses of dabigatran

British Medical Journal
According to an investigation by the BMJ, Boehringer Ingelheim withheld from doctors and drug regulators the fact that monitoring the blood level of dabigatran and adjusting the dose could substantially reduce major bleeds associated with it.

 

Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182) – guidance (TA317)

National Institute for Health and Care Excellence
Prasugrel in combination with aspirin is recommended as an option for preventing atherothrombotic events in adults with acute coronary syndrome (unstable angina, non-ST or ST segment elevation myocardial infarction) having primary or delayed percutaneous coronary intervention.

 

Catheter ablation of atrial fibrillation: an update

European Heart Journal
Recent clinical trial data have demonstrated the superiority of catheter ablation of AF to antiarrhythmic drug therapy in controlling AF. However, it is a challenging and complex procedure and therefore not used as a first line treatment option in clinical practice.

 

Antiplatelet therapy for secondary prevention of coronary artery disease

Heart
This review summarizes the currently available evidence on choice, combination and duration of antiplatelet agents in stable coronary artery disease and acute coronary syndrome.

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:
http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services